| Literature DB >> 30379929 |
Jui-Ying Fu1,2, Yung-Liang Wan1,3, Tzu-Yen Huang1,4, Ching-Feng Wu1,5, Yun-Hen Liu1,5, Ming-Ju Hsieh1,5, Yi-Cheng Wu1,5, Ching-Yang Wu1,5.
Abstract
INTRODUCTION: Tumor characteristics in computed tomography (CT) are correlated to pathologic presentation and survival. However, most studies have been based on thin slice thickness CT while lymph node metastatic pattern has remained unclear. The aim of this study was to analyze the correlation between image characteristics under 5 mm slice thickness and pathology findings in non small lung cancer patients who have received curative resection.Entities:
Mesh:
Year: 2018 PMID: 30379929 PMCID: PMC6209293 DOI: 10.1371/journal.pone.0206386
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Exclusion algorithm.
Fig 2Definition of consolidation tumor ratio (B/A).
A: Maximal diameter of the consolidation part of the tumor was measured in CT cross section under lung window view. B: Maximal diameter of the consolidation part of the tumor was measured in CT cross section under mediastinal window.
Fig 3Classifications of tumor component.
A. Pure ground glass opacity (GGO) B. Ground glass predominant C. Solid predominant D. Pure solid.
Descriptive data for non small cell lung cancer patients who received anatomic resection.
| Variables | (Mean ± SD)/ Mean (%) | Variables | (Mean ± SD)/ Mean (%) |
|---|---|---|---|
| Age¤ | 62.06±11.40 | Cell type | |
| Gender Female | 213 (48.41) | Adenocarcinoma | 335 (76.14) |
| Body height | 160.47±11.13 | Squamous cell carcinoma | 44 (10.00) |
| Body weight | 63.08±11.13 | Mucinous Adenocarcinoma | 10 (2.27) |
| CT finding Tumor size | 3.35±1.82 | Lympho-epithelioma-like carcinoma | 10 (2.27) |
| CT finding Tumor ratio | 0.72±0.28 | Other | 41 (9.32) |
| CT tumor component | Tumor purity | 0.41±0.38 | |
| Pure GGO | 33 (7.57) | ||
| GGO predominant | 44 (10.09) | ||
| Solid predominant | 269 (61.70) | ||
| Pure Solid | 90 (20.64) | ||
| Other | 4 | ||
| VATS/Thoracotomy | Differentiated grade | ||
| Thoracotom | 7 (1.6) | G1 | 201 (45.68) |
| VATS→Thoracotomy | 28 (6.36) | G2 | 138 (31.36) |
| VATS | 405 (92.05) | G3 | 57 (12.95) |
| Total staplers | 7.97±2.82 | G4 | 16 (3.64) |
| Blood Loss (ml) | 115.40±236.62 | N/A | 28 (6.36) |
| OR time (min) | 208.14±57.14 | Lymph node status | |
| Post OP days | 8.46±8.56 | Total LN No. | 21.22±11.03 |
| Postoperative in-hospital stay | 13.27±10.77 | Metastatic N1 LN No. | 0.42±1.10 |
| ICU stay (days) | 0.78±6.17 | Metastatic N2 LN No. | 0.40±1.31 |
| In hospital mortality | 0 | Pathologic stage (AJCC 7th ed) | |
| Visceral pleural invasion | 155 (35.22) | Premalignant lesion | 1 (0.23) |
| Angiolymphatic invasion | 123 (27.95) | 1a | 148 (33.64) |
| Tumor necrosis | 158 (37.80) | 1b | 141 (32.05) |
| Lymphocyte infiltrates | 2a | 49 (11.14) | |
| Minimal +Mild | 267 (64.96) | 2b | 32 (7.27) |
| Moderate + Marked | 144 (35.04) | 3a | 69 (15.68) |
1 3 patients had endobronchial lesion, 1 patient had central tumor necrosis
2 Vessel injury: 10 (2 pulmonary vein; 8 pulmonary artery); Resectability evaluation: 17; Airway reconstruction: 1
3 missing data in 22 patients
4 missing data in 29 patients
Correlation between CT tumor component and pathologic findings.
| Tumor size | Mean ± SD (cm)/(%) | Association | ||||
|---|---|---|---|---|---|---|
| Pathology tumor size | 2.99±1.63 | p <0.001 | ||||
| CT finding tumor size | 2.97±1.85 | |||||
| Component | Pure GGO | GGO dominant | Solid dominant | Pure solid | ||
| Item | ||||||
| Adenocarcinoma | 32 (97) | 43 (97.7) | 221 (89.6) | 48 (53.3) | p<0.0001 | |
| Well differentiated | 30 (93.9) | 31 (70.5) | 125 (48.3) | 15 (19.7) | p <0.0001 | |
| LN invasion status | 0.03±0.17 | 0.25±0.87 | 0.39±0.98 | 0.75±1.60 | p = 0.004 | |
| Visceral pleural invasion | 0 | 17(38.6) | 92 (34.3) | 46 (50.1) | p<0.0001 | |
| Angiolymphatic invasion | 1 (3.4) | 8 (19.2) | 83 (31) | 31 (34.4) | p<0.002 | |
| Tumor necrosis | 3 (9.38) | 10 (23.81) | 90 (35.43) | 55 (63.22) | p<0.0001 | |
| Lymphocyte infiltrates | 25 (78.13) | (66.67) | 166 (66.67) | 45 (52.94) | p = 0.042 | |
| Tumor purity | 0.08±0.13 | 0.18±0.24 | 0.39±0.36 | 0.64±0.40 | p<0.0001 | |
1 4 patients were excluded from analysis (3 patients had endobronchial lesion, 1 patient had central tumor necrosis)
2 29 patients were excluded from analysis (28 patients had no pathologic data for cell differentiation grade, 1 patient was confirmed atypical adenomatous hyperplasia)
3 1 patient presenting as premalignant change without angiolymphatic invasion was excluded
4 missing data in 22 patients
5 missing data in 29 patients
6 Pearson correlation, coefficient = 0.67
7 chi-square test
8 Fisher exact test
9 Linear model
10 Cox regression
Tumor component vs. lymph node metastatic pattern in different tumor sizes.
| Component | Pure GGO | GGO dominant | Solid dominant | Pure solid | |||||||||||||||||
| Size | A | B | C | D | A | B | C | D | A | B | C | D | A | B | C | D | |||||
| Lymph node status | |||||||||||||||||||||
| No LN metastases | 12 | 12 | 7 | 1 | 3 | 10 | 19 | 6 | 9 | 50 | 78 | 64 | 1 | 5 | 19 | 33 | |||||
| N1 metastases only | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 6 | 8 | 17 | 0 | 0 | 3 | 10 | |||||
| N2 metastases | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 5 | 7 | 0 | 0 | 0 | 5 | |||||
| N1/N2 metastases | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 4 | 6 | 11 | 0 | 1 | 3 | 10 | |||||
| No LN metastases | N1 LN metastases | N2 LN metastases | N1/N2 LN metastases | Total LN metastases | |||||||||||||||||
| A2 | B2 | C2 | D2 | A | B | C | D | A | B | C | D | A | B | C | D | A | B | C | D | ||
| 25 | 77 | 123 | 104 | 0 | 6 | 14 | 28 | 1 | 3 | 6 | 12 | 0 | 6 | 10 | 21 | 1 | 15 | 30 | 61 | ||
14 patients were excluded due to central necrosis (1) and endobronchial lesion (3)
2A: tumor <1 cm (N = 26); B: 1cm < size ≤ 2cm (N = 92); C: 2 cm< size ≤ 3 cm (N = 153); D: size > 3 cm (N = 165)
Multivariable analysis for disease free and overall survival (cox proportion hazard model).
| Multivariable analysis for disease free survival (Cox proportion hazard model) | |||||
| Statistical results | Parameter estimate | Standard Error | 95% confidence interval | P value | |
| Variable | |||||
| Gender | -0.38 | 0.17 | 0.49,0.95 | 0.02 | |
| CT tumor size | 0.38 | 0.20 | 0.98,2.18 | 0.06 | |
| GGO | -1.07 | 0.31 | 0.19,0.62 | 0.000 | |
| Thoracotomy vs. VATS | 0.29 | 0.28 | 0.78,2.31 | 0.28 | |
| Multivariable analysis for Overall survival (Cox proportion hazard model) | |||||
| Statistical results | Parameter estimate | Standard Error | 95% confidence interval | P value | |
| Variable | |||||
| Gender | -0.19 | 0.34 | 0.43,1.59 | 0.56 | |
| Smoke | 0.68 | 0.32 | 1.06,3.66 | 0.03 | |
| CT tumor size | 0.46 | 0.34 | 0.82,3.06 | 0.17 | |
| GGO | -1.05 | 0.52 | 0.13,0.98 | 0.04 | |
| Thoracotomy vs. VATS | 0.62 | 0.33 | 0.98,3.56 | 0.06 | |
Fig 4Disease free and overall survival for non small cell lung cancer patients for different C/T ratios.
A. Disease free survival for non small cell lung cancer patients with different C/T ratio (p <0.0001) B. Overall survival for non small cell lung cancer patients with different C/T ratio (p = 0.0043).